ロード中...
Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells
Glioblastoma (GBM) cells are characterized by high phagocytosis, lipogenesis, exocytosis activities, low autophagy capacity and high lysosomal demand are necessary for survival and invasion. The lysosome stands at the cross roads of lipid biosynthesis, transporting, sorting between exogenous and end...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5805523/ https://ncbi.nlm.nih.gov/pubmed/29467937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23855 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|